Br[C:2]1[CH:11]=[CH:10][C:9]2[N:8]=[CH:7][C:6]3[NH:12][C:13](=[O:42])[CH2:14][N:15]([C:16]4[CH:21]=[CH:20][C:19]([N:22]5[CH2:27][CH2:26][CH:25]([C:28]([NH:30][CH:31]6[CH2:36][CH2:35][N:34]([CH3:37])[CH2:33][CH2:32]6)=[O:29])[CH2:24][CH2:23]5)=[C:18]([C:38]([F:41])([F:40])[F:39])[CH:17]=4)[C:5]=3[C:4]=2[CH:3]=1.[N:43]1[C:52]2[C:47](=[CH:48][CH:49]=[CH:50][CH:51]=2)[CH:46]=[C:45](B(O)O)[CH:44]=1.CC(C1C=C(C(C)C)C(C2C(P(C(C)(C)C)C(C)(C)C)=CC=CC=2)=C(C(C)C)C=1)C>O1CCOCC1.C(=O)([O-])[O-].[Na+].[Na+]>[CH3:37][N:34]1[CH2:33][CH2:32][CH:31]([NH:30][C:28]([CH:25]2[CH2:24][CH2:23][N:22]([C:19]3[CH:20]=[CH:21][C:16]([N:15]4[C:5]5[C:4]6[CH:3]=[C:2]([C:45]7[CH:44]=[N:43][C:52]8[C:47]([CH:46]=7)=[CH:48][CH:49]=[CH:50][CH:51]=8)[CH:11]=[CH:10][C:9]=6[N:8]=[CH:7][C:6]=5[NH:12][C:13](=[O:42])[CH2:14]4)=[CH:17][C:18]=3[C:38]([F:41])([F:40])[F:39])[CH2:27][CH2:26]2)=[O:29])[CH2:36][CH2:35]1To a solution of 8.5 1-(4-(9-bromo-3-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)-N-(1-methylpiperidin-4-yl)piperidine-4-carboxamide (46 mg, 0.07 mmol, 1 equiv.) in dioxane (2 mL) and 1N sodium carbonate solution (0.6 mL) in a sealed tube at room temperature was added 7 quinolin-3-yl-boronic acid (24 mg, 0.14 mmol, 2 equiv.), t-butyl-Xphos (3 mg, 0.007 mmol, 0.1 equiv.), and PdCl2(Ph3P)2 (4.9 mg, 0.007 mmol, 0.1 equiv.). The resulting mixture was degassed, sealed and heated overnight to 100° C. Upon cooling to room temperature, the reaction mixture was filtered through celite and washed with EtOAc (2 mL). The collected solution was evaporated and the residue was purified via HPLC to afford the desired product 8.6 N-(1-methylpiperidin-4-yl)-1-(4-(3-oxo-9-(quinolin-3-yl)-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)piperidine-4-carboxamide 1.5 mg. LC-MS: (M+H) 694.40